Oncology Medicinal Chemistry, GlaxoSmithKline, 1250 S. Collegeville, Rd., Collegeville, PA 19426, United States.
Bioorg Med Chem Lett. 2010 Jan 15;20(2):673-8. doi: 10.1016/j.bmcl.2009.11.064. Epub 2009 Nov 20.
2,3,5-Trisubstituted pyridines have been designed as potent AKT inhibitors that are selective against ROCK1 based on the comparison between AKT and ROCK1 structures. Substitution at the 2-position of the core pyridine is the key element to provide selectivity against ROCK1. An X-ray co-crystal structure of 9p in PKA supports the proposed rationale of ROCK1 selectivity.
2,3,5-三取代吡啶被设计为强效 AKT 抑制剂,其基于 AKT 和 ROCK1 结构的比较,对 ROCK1 具有选择性。核心吡啶的 2-位取代是提供对 ROCK1 选择性的关键因素。9p 在 PKA 中的 X 射线共晶结构支持 ROCK1 选择性的提出原理。